639 related articles for article (PubMed ID: 33859752)
1. Turning cold tumors into hot tumors by improving T-cell infiltration.
Liu YT; Sun ZJ
Theranostics; 2021; 11(11):5365-5386. PubMed ID: 33859752
[TBL] [Abstract][Full Text] [Related]
2. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors.
Ouyang P; Wang L; Wu J; Tian Y; Chen C; Li D; Yao Z; Chen R; Xiang G; Gong J; Bao Z
Front Immunol; 2024; 15():1344272. PubMed ID: 38545114
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for Gallium-67 SPECT in distinguishing progression and pseudoprogresion in oncologic patients receiving immunotherapy?
Mauri D; Tsiouris S; Gkoura S; Gazouli I; Ntellas P; Amylidis A; Kampletsas L; Fotopoulos A
Cancer Treat Res Commun; 2021; 28():100441. PubMed ID: 34404012
[TBL] [Abstract][Full Text] [Related]
4. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
Cho H; Kim K
Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
[TBL] [Abstract][Full Text] [Related]
5. Immunologic tumor microenvironment modulators for turning cold tumors hot.
Khosravi GR; Mostafavi S; Bastan S; Ebrahimi N; Gharibvand RS; Eskandari N
Cancer Commun (Lond); 2024 May; 44(5):521-553. PubMed ID: 38551889
[TBL] [Abstract][Full Text] [Related]
6. Challenges and exploration for immunotherapies targeting cold colorectal cancer.
Li DD; Tang YL; Wang X
World J Gastrointest Oncol; 2023 Jan; 15(1):55-68. PubMed ID: 36684057
[TBL] [Abstract][Full Text] [Related]
7. Igniting Hope for Tumor Immunotherapy: Promoting the "Hot and Cold" Tumor Transition.
Wei C; Ma Y; Wang F; Liao Y; Chen Y; Zhao B; Zhao Q; Wang D; Tang D
Clin Med Insights Oncol; 2022; 16():11795549221120708. PubMed ID: 36147198
[TBL] [Abstract][Full Text] [Related]
8. Cold Tumors: A Therapeutic Challenge for Immunotherapy.
Bonaventura P; Shekarian T; Alcazer V; Valladeau-Guilemond J; Valsesia-Wittmann S; Amigorena S; Caux C; Depil S
Front Immunol; 2019; 10():168. PubMed ID: 30800125
[TBL] [Abstract][Full Text] [Related]
9. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
11. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
Esposito A; Criscitiello C; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
[TBL] [Abstract][Full Text] [Related]
14. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Collins JM; Redman JM; Gulley JL
Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
[TBL] [Abstract][Full Text] [Related]
15. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.
Lynn GM; Laga R; Jewell CM
Cancer Lett; 2019 Sep; 459():192-203. PubMed ID: 31185250
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies.
Wang L; Zhang W; Zhang J; Zheng M; Pan X; Guo H; Ding L
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 52(5):567-577. PubMed ID: 37916308
[TBL] [Abstract][Full Text] [Related]
17. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Leko V; Rosenberg SA
Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
[TBL] [Abstract][Full Text] [Related]
18. Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.
Chen Q; Sun T; Jiang C
Nanomicro Lett; 2021 Mar; 13(1):92. PubMed ID: 34138315
[TBL] [Abstract][Full Text] [Related]
19. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ; Chen JX; Sun ZJ
Cancer Commun (Lond); 2021 Sep; 41(9):830-850. PubMed ID: 34137513
[TBL] [Abstract][Full Text] [Related]
20. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy.
Melero I; Rouzaut A; Motz GT; Coukos G
Cancer Discov; 2014 May; 4(5):522-6. PubMed ID: 24795012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
